Allogene Therapeutics initiated at Piper Jaffray

Allogene Therapeutics initiated with an Overweight at Piper Jaffray. Piper Jaffray analyst Tyler Van Buren started Allogene Therapeutics with an Overweight rating and $50 price target. The company is well positioned to deliver on the promises of allogeneic CAR-T therapy given the prior success of its “world-class” management team in the autologous setting and the initial strategy to pursue de-risked targets, Van Buren tells investors in a research note. He calls the initial efficacy data from UCART19 “competitive” and is optimistic about the ability for an anti-CD52-containing lymphodepletion regimen to “meaningfully increase” donor CAR-T cell expansion.

https://thefly.com/landingPageNews.php?id=2885911